Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 10.24
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of NVNO is 13 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
Buy
Sell